Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:

interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC

clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
Clinical Trials Information System (CTIS).

The EU Clinical Trials Register currently displays 44364 clinical trials with a EudraCT protocol, of which 7388 are clinical trials conducted with subjects less than 18 years old. The register also displays information on 18700 older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).

Examples: Cancer AND drug name. Pneumonia AND sponsor name.
How to search [pdf]

Advanced Search:

Search tools

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Trials with a EudraCT protocol (44,364)
Paediatric studies in scope of Art45 of the Paediatric Regulation (18,700)

44,364 result(s) found. Displaying page 1,786 of 2,219.

EudraCT Number: 2021-002308-11

Sponsor Protocol Number: IM047-001

Start Date*: 2021-12-22

Sponsor Name:Celgene International II Sàrl

Full Title: A phase 2/3, multicenter, randomized, double-blind study to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of oral ozanimod (RPC1063) in pediatric subjects with moderately to ...

Medical condition: Moderately to Severely Active Ulcerative Colitis

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.1	100000004856	10045365	Ulcerative colitis	LLT

Population Age: Children, Adolescents, Under 18

Gender: Male, Female

Trial protocol: FR (Trial now transitioned) PL (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2020-000309-10

Sponsor Protocol Number: CHUBX2017/45

Start Date*: 2021-10-04

Sponsor Name:CHU de Bordeaux

Full Title: Phase II/III double-blind randomized placebo-controlled trial assessing the preventive effect of Clopidogrel on the systemic sclerosis development risk in subjects with specific dysimmunity and Ray...

Medical condition: Raynaud phenomenon

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	100000004866	10037914	Raynaud's syndrome	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2020-005896-12

Sponsor Protocol Number: CBYL719F12401

Start Date*: 2021-10-20

Sponsor Name:Novartis Pharma AG

Full Title: EPIK-P3: A phase II study to evaluate the long-term safety and efficacy of alpelisib in patients with PIK3CA-Related Overgrowth Spectrum (PROS) who previously participated in Study CBYL719F12002 (E...

Medical condition: PIK3CA-related overgrowth spectrum (PROS)

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.1	10010331 - Congenital, familial and genetic disorders	10081236	PIK3CA related overgrowth spectrum	PT

Population Age: Children, Adolescents, Under 18, Adults

Gender: Male, Female

Trial protocol: FR (Trial now transitioned) IE (Trial now transitioned) ES (Ongoing)

Trial results: (No results available)

EudraCT Number: 2021-003478-30

Sponsor Protocol Number: CAAA802A12101

Start Date*: 2022-08-15

Sponsor Name:Novartis Pharma AG

Full Title: SatisfACtion: A Phase I/II, open-label, multi-center study of [225Ac]Ac-PSMA-R2 in men with heavily pre-treated PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) with or without...

Medical condition: PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC) with or without prior 177Lu-PSMA radioligand therapy.

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	100000004864	10036908	Prostatic neoplasms malignant	HLT

Population Age: Adults, Elderly

Gender: Male

Trial protocol: FR (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2021-000161-32	Sponsor Protocol Number: CLIN-52120-452	Start Date*: 2021-08-11
Sponsor Name:Ipsen Pharma
Full Title: A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport®) in Comparison with Onabotulinu...
Medical condition: upper limb spasticity (ULS) of any aetiology (in US and France) or post-stroke ULS (in Canada)
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: FR (Trial now transitioned)
Trial results: (No results available)

EudraCT Number: 2018-004124-10

Sponsor Protocol Number: 68284528MMY2003

Start Date*: 2020-08-07

Sponsor Name:Janssen-Cilag International NV

Full Title: A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma

Medical condition: Multiple Myeloma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.0	100000004864	10028228	Multiple myeloma	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2014-001578-32	Sponsor Protocol Number: 2012/49	Start Date*: 2014-11-10
Sponsor Name:CENTRE ANTOINE LACASSAGNE
Full Title: A phase I/II study of pazopanib in combination with temozolomide in patients with newly diagnosed glioblastoma multiforme after surgery and RT-CT (PAZOGLIO study)
Medical condition: Glioblastoma
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: FR (Trial now transitioned)
Trial results: (No results available)

EudraCT Number: 2017-002400-26

Sponsor Protocol Number: 64407564MMY1001

Start Date*: 2019-02-06

Sponsor Name:Janssen-Cilag International NV

Full Title: A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma

Medical condition: Relapsed or Refractory Multiple Myeloma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	10010331 - Congenital, familial and genetic disorders	10005330	Blood and lymphatic system disorders congenital	HLGT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: NL (Trial now transitioned) DE (Trial now transitioned) PL (Trial now transitioned) FR (Trial now transitioned) BE (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2020-001685-11	Sponsor Protocol Number: ICO-2020-01	Start Date*: 2020-06-26
Sponsor Name:INSTITUT DE CANCEROLOGIE DE L'OUEST
Full Title: RElapse in previously irradiated Prostate bed : a phase I/II study of stereotactic Ablative reIRradiation potentiated by Metformine
Medical condition: RElapse in previously irradiated Prostate bed
Disease:
Population Age: Adults		Gender: Male
Trial protocol: FR (Trial now transitioned)
Trial results: (No results available)

EudraCT Number: 2019-003047-30

Sponsor Protocol Number: 209664

Start Date*: 2020-02-14

Sponsor Name:GlaxoSmithKline Research & Development Ltd

Full Title: A Phase 3, Randomized, Open-Label Study of Belantamab Mafodotin Administered in Combination with Bortezomib, Lenalidomide and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone Alone i...

Medical condition: Multiple Myeloma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.0	100000004864	10028228	Multiple myeloma	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2018-000186-36

Sponsor Protocol Number: IB2017-04

Start Date*: 2019-01-07

Sponsor Name:Institut Bergonié

Full Title: Phase III trial investigating the potential benefit of intensified peri-operative Chemotherapy in patients with in high-risk CINSARC patients with resectable soft-tissue SARComas

Medical condition: Resectable, non-metastatic soft-tissue sarcoma (STS)

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	100000004864	10039494	Sarcoma NOS	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2007-007616-28

Sponsor Protocol Number: RV-MM-PI-302

Start Date*: 2008-01-31

Sponsor Name:FONDAZIONE NEOPLASIE SANGUE ONLUS

Full Title: A MULTICENTER, OPEN LABEL STUDY OF ORAL REVLIMID AND PREDNISONE (RP) FOLLOWED BY ORAL REVLIMID MELPHALAN AND PREDNISONE (MPR) IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS

Medical condition: NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	9.1		10028229	Multiple myelomas	HLT

Population Age: Elderly

Gender: Male, Female

Trial protocol: IT (Completed)

Trial results: View results

EudraCT Number: 2017-000087-15

Sponsor Protocol Number: BP39529

Start Date*: 2017-12-21

Sponsor Name:F. Hoffmann-La Roche Ltd

Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, 52-WEEK PHASE II STUDY TO EVALUATE THE EFFICACY OF INTRAVENOUS RO7046015/PRASINEZUMAB (PRX002) IN PARTICIPANTS WITH EARLY PARKINSON'S DISEASE WITH A 6...

Medical condition: Parkinson’s disease

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	10029205 - Nervous system disorders	10061536	Parkinson's disease	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned)

Trial results: View results

EudraCT Number: 2019-003610-13

Sponsor Protocol Number: MK-3475-03B

Start Date*: 2020-12-01

Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Full Title: A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants With RCC (U03): Substudy 03B

Medical condition: Renal Cell Carcinoma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	100000004864	10038409	Renal cell carcinoma NOS	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Trial now transitioned) HU (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2009-011470-15

Sponsor Protocol Number: AC-058B202

Start Date*: 2010-03-30

Sponsor Name:ACTELION Pharmaceuticals Ltd

Full Title: Multicenter, randomized, double-blind, parallel-group extension to study AC 058B201 to investigate the long-term safety, tolerability, and efficacy of 10, 20, and 40 mg/day ponesimod, an oral S1P1 ...

Medical condition: relapsing-remitting multiple sclerosis

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.1	10029205 - Nervous system disorders	10063399	Relapsing-remitting multiple sclerosis	PT

Population Age: Adults

Gender: Male, Female

Trial protocol: FI (Completed) SE (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) CZ (Completed) DE (Completed) BG (Completed) PL (Completed) HU (Completed) NL (Completed) AT (Completed) IT (Completed)

Trial results: View results

EudraCT Number: 2009-015844-41

Sponsor Protocol Number: BMN162-502

Start Date*: 2013-07-25

Sponsor Name:BioMarin International Ltd.

Full Title: A Phase IV Open-Label, Single-Cohort Study of the Long-Term Neurocognitive Outcomes in 4 to 5 Year-Old Children with Phenylketonuria Treated with Sapropterin Dihydrochloride (Kuvan®) for 7 Years.

Medical condition: Phenylketonuria

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	19.0	100000004850	10034873	Phenylketonuria (PKU)	LLT

Population Age: Children, Under 18

Gender: Male, Female

Trial protocol: GB (Completed) DE (Completed) IT (Completed) ES (Completed)

Trial results: View results

EudraCT Number: 2009-018083-94

Sponsor Protocol Number: IEO S513/110

Start Date*: 2010-07-29

Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA

Full Title: Nonmyeloablative Hematopoietic Stem Cell Transplantation for Patients with High-Risk Hematologic Malignancies using Related, HLA-Haploidentical Donors: A Phase II Trial of Combined Immunosuppressio...

Medical condition: High risk Hematologic Malignancies

Disease:	Version	SOC Term	Classification Code	Term	Level
	9.1		10024324		HLGT
	9.1		10025323		HLGT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: IT (Completed)

Trial results: (No results available)

EudraCT Number: 2010-020337-99

Sponsor Protocol Number: WA21092

Start Date*: 2011-10-20

Sponsor Name:F.Hoffmann-La Roche

Full Title: A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sc...

Medical condition: Relapsing Multiple Sclerosis

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.1	10029205 - Nervous system disorders	10063399	Relapsing-remitting multiple sclerosis	PT

Population Age: Adults

Gender: Male, Female

Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) CZ (Completed) LV (Completed) HU (Completed) FI (Completed) DE (Completed) BE (Completed) SK (Completed) AT (Completed) NL (Ongoing) LT (Completed) EE (Completed) PT (Completed) BG (Completed) ES (Ongoing) PL (Completed) IT (Completed)

Trial results: View results

EudraCT Number: 2010-020338-25

Sponsor Protocol Number: WA25046

Start Date*: 2010-11-02

Sponsor Name:F.Hoffmann-La Roche

Full Title: A Phase III, multicenter, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy and safety of ocrelizumab in adults with Primary Progressive Multiple Sclerosis

Medical condition: Primary Progressive Multiple Sclerosis (PPMS)

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.1	10029205 - Nervous system disorders	10063401	Primary progressive multiple sclerosis	PT

Population Age: Adults

Gender: Male, Female

Trial protocol: LT (Completed) ES (Ongoing) BE (Completed) FR (Completed) HU (Completed) NL (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) DE (Completed) PT (Completed) AT (Completed) FI (Completed) IT (Completed) GR (Completed) BG (Completed) DK (Prematurely Ended) PL (Completed)

Trial results: View results

EudraCT Number: 2010-020315-36

Sponsor Protocol Number: WA21093

Start Date*: 2011-10-18

Sponsor Name:F.Hoffmann-La Roche

Medical condition: Relapsing Multiple Sclerosis

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.1	10029205 - Nervous system disorders	10063399	Relapsing-remitting multiple sclerosis	PT

Population Age: Adults

Gender: Male, Female

Trial protocol: SK (Completed) BE (Completed) SE (Completed) DE (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) BG (Completed) FR (Completed) IE (Completed) IT (Completed) CZ (Completed)

Trial results: View results

Subscribe to this Search
To subscribe to the RSS feed for this search click here

. This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.

Download Options:
Number of Trials to download:

Download Content:

Download Format:


Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.

Query did not match any studies.

For support, Contact us.

The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

European Medicines Agency © 1995-Mon Nov 17 15:11:35 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA